Lymphoma, Non-Hodgkin — Cardiac Safety Study of Brentuximab Vedotin (SGN-35)
Citation(s)
An Intensive QT/QTc Study to Investigate the Effects of SGN-35 (Brentuximab Vedotin) on Cardiac Ventricular Repolarization in Patients With CD30-Positive Malignancies